Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction – MarketWatch (press release)

by admin on March 19, 2013


MarketWatch (press release)
Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
MarketWatch (press release)
Omeros also believes that it controls the worldwide rights to any PDE7 inhibitor for the treatment of any movement disorder, including Parkinson's disease, restless leg syndrome and Huntington's disease. Omeros has licensed its PDE7 inhibitors from

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: